Imino acid PET imaging agent, and preparation method and application thereof

A PET imaging agent, imino acid technology, applied in organic chemistry methods, cyanide reaction preparation, chemical instruments and methods, etc., can solve the problems of complex metabolic mechanism and difficult in vivo quantitative research.

CN103333079AActive Publication Date: 2013-10-02GUANGDONG HUIXUAN PHARMA TECH
9 Cites 10 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2013-10-02

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses an amino acid positron emission tomography (PET) imaging agent, and a preparation method and application thereof. The imaging agent belongs to the field of N-substituted positron nuclide labeled glutamic acid compound and has a structure as shown in the specification; and the L*represents -11CH3, CH2CH218F, and -COCH (18F) CH3. The novel imaging agent N-(2-18F-fluoropropionyl)-glutamic acid shows good tumor PET imaging sensitivity and specificity, has high uptake on tumor (such as S180 fibrosarcoma), and no obvious uptake on other tissues and organs (except for bladder) in the body, and indicates high tumor to background ratio. In vitro-in vivo experiments show that N-(2 - 18F -fluoropropionyl)-glutamic acid is stable in vitro and in vivo and shows good pharmacokinetic properties.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to imino acid positron emission tomography (PET) imaging agent and its preparation method and application, especially N-(2- 18 F-fluoropropionyl)-glutamic acid and N- 11 A preparation method of C-methyl-glutamic acid and its application to tumor PET imaging. Background technique

[0002] 18 F-fluorodeoxyglucose ( 18 F-FDG) is currently the most commonly used glucose-metabolizing PET imaging agent. It has been successfully used in various clinical aspects, such as the identification of benign and malignant tumors, the evaluation of the malignant degree of tumors, and the monitoring of tumor treatment effects. but 18 F-FDG also has problems such as poor specificity, some tumor cells do not take it up, and inflammatory cells also take it up, which leads to certain false positive or false negative results in the differential diagnosis of tumors. The growth of tumor cells not only requires a large amount of glucose intake,...

Examples

Embodiment Construction

[0018] The present invention will be described in detail below in conjunction with specific embodiments.

[0019] 1. Materials and methods

[0020] 1.1 Instruments, reagents and experimental animals

[0021] Fluorine multifunctional chemical synthesis module PET-MF-2V-IT-I and carbon multifunctional module (Beijing Petrobio Co., Ltd., China); Agilent 1200 analytical HPLC analyzer (Agilent, USA); trifluoroform Silver sulfonyl (ACROS company, the United States); ethyl 2-bromopropionate, bis(p-nitrophenyl) carbonate, silver wire and graphite powder: 80 (Aldrich, the United States); phosphorus pentoxide (Beijing Chemical Reagent ); high performance liquid chromatography radioactive detector (Bioscan, USA); Cyclone10 / 5 cyclotron (IBA, Belgium); PET / CT () MicroPET (Siemens, Germany). Sep Pak QMA, Sep Pak HLB, Sep Pak C18 (Water, USA). PET-CT Gemini GXL scanner (Philips, Holland).

[0022] All experimental animals and cells were from the Animal Center of Sun Yat-Sen University, a...